An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System

Neutropenia Clinical Trial

Official title:

Efficacy And Safety Of Eraxis/Ecalta (Anidulafungin) Compared To Cancidas (Caspofungin) In Neutropenic Patients With Invasive Candida Infection

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00806351
• Other study ID #: A8851021
• Status: Terminated
• Phase: Phase 3
• First received: November 26, 2008
• Last updated: November 20, 2012
• Start date: August 2009
• Est. completion date: October 2011

Study information

• Verified date: November 2012
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to gather information on the use of anidulafungin for the treatment of Candida infection in patients with an abnormal immune system. It is expected that anidulafungin will be at least as safe and as effective as the comparator drug, caspofungin.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 21
• Est. completion date: October 2011
• Est. primary completion date: October 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

• Dysfunctional immune system (reduced neutrophils).

• Confirmed Candida infection, defined as growth of Candida from a normally sterile site accompanied by signs and symptoms of infection.

• Male of female =16 years of age.

• Expected hospitalization for at least ten (10) days.

Exclusion Criteria:

• Pregnancy or breast feeding or planning to become pregnant during the study.

• Recent treatment with one of the study drugs over the last 30 days.

• Allergy to either study drug or to this class of drugs.

• Significant liver dysfunction.

• Suspected Candida osteomyelitis, endocarditis, meningitis or any other infections of the central nervous system.

Related Conditions & MeSH terms

• Candidiasis
• Fungemia
• Infection
• Mycoses
• Neutropenia

Intervention

Drug:
• Active Anidulafungin
Subjects in this arm will receive active anidulafungin and placebo caspofungin
• Active Caspofungin
Subjects in this arm will receive active caspofungin and placebo anidulafungin

Locations

Country	Name	City	State
Bosnia and Herzegovina	Pfizer Investigational Site	Sarajevo
France	Pfizer Investigational Site	GRENOBLE Cedex 09
France	Pfizer Investigational Site	Strasbourg Cedex
Italy	Pfizer Investigational Site	Bologna
Italy	Pfizer Investigational Site	Roma
Poland	Pfizer Investigational Site	Gdansk
Poland	Pfizer Investigational Site	Warszawa
Poland	Pfizer Investigational Site	Wroclaw
Russian Federation	Pfizer Investigational Site	Moscow
Slovakia	Pfizer Investigational Site	Kosice

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Countries where clinical trial is conducted

Bosnia and Herzegovina,  France,  Italy,  Poland,  Russian Federation,  Slovakia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Global Response at End of Intravenous Treatment (EOIVT)	Participant counts of global response of success, failure, or indeterminate. Success: clinical response of cure (no signs, symptoms [s/s] of Candida) or improvement (significant, incomplete resolution of s/s) and microbiological response of eradication (follow-up [f/u] culture negative) or presumed eradication (f/u culture not available and clinical success). Failure: clinical response of failure (greater than or equal to [=3] doses study medication and no significant improvement of s/s or death due to Candida) and/or unsuccessful microbiological response of persistent(positive culture any Candida species [sp]), new infection or relapse at f/u. Indeterminate: clinical and/or microbiological response of indeterminate (evaluation could not be made due to withdrawal from study prior to assessment of cure or failure) and there was neither clinical response of failure nor unsuccessful microbiological response (persistence or new infection or relapse).	Day 10 up to Day 42
Secondary	Global Response at End of Treatment (EOT)	Participant counts of global response of success, failure, or indeterminate. Success: clinical response of cure (no s/s of Candida) or improvement (significant, incomplete resolution of s/s) and microbiological response of eradication (f/u culture negative) or presumed eradication (f/u culture not available and clinical success). Failure: clinical response of failure (=3 doses study medication and no significant improvement of s/s or death due to Candida) and/or unsuccessful microbiological response of persistent (positive culture any Candida sp), new infection or relapse at f/u. Indeterminate: clinical and/or microbiological response of indeterminate (evaluation could not be made due to withdrawal from study prior to assessment of cure or failure) and there was neither clinical response of failure nor unsuccessful microbiological response (persistence or new infection or relapse).	Day 14 up to Day 56
Secondary	Global Response at 2-Week Follow-Up Visit	Participant counts of global response of success, failure, or indeterminate. Success: clinical response of cure (no s/s of Candida) or improvement (significant, incomplete resolution of s/s) and microbiological response of eradication (f/u culture negative) or presumed eradication (f/u culture not available and clinical success). Failure: clinical response of failure (=3 doses study medication and no significant improvement of s/s or death due to Candida) and/or unsuccessful microbiological response of persistent (positive culture any Candida sp), new infection or relapse at f/u. Indeterminate: clinical and/or microbiological response of indeterminate (evaluation could not be made due to withdrawal from study prior to assessment of cure or failure) and there was neither clinical response of failure nor unsuccessful microbiological response (persistence or new infection or relapse).	2 weeks post treatment
Secondary	Global Response at 6-Week Follow-Up Visit	Participant counts of global response of success, failure, or indeterminate. Success: clinical response of cure (no s/s of Candida) or improvement (significant, incomplete resolution of s/s) and microbiological response of eradication (f/u culture negative) or presumed eradication (f/u culture not available and clinical success). Failure: clinical response of failure (=3 doses study medication and no significant improvement of s/s or death due to Candida) and/or unsuccessful microbiological response of persistent (positive culture any Candida sp), new infection or relapse at f/u. Indeterminate: clinical and/or microbiological response of indeterminate (evaluation could not be made due to withdrawal from study prior to assessment of cure or failure) and there was neither clinical response of failure nor unsuccessful microbiological response (persistence or new infection or relapse).	6 weeks post treatment
Secondary	Response Based on Clinical Cure and Microbiological Success at EOIVT	Participant counts of clinical cure (no s/s of Candida) and microbiological success (eradication [f/u culture negative] or presumed eradication [f/u culture not available and a clinical response of cure]).	Day 10 up to Day 42
Secondary	Response Based on Clinical Cure and Microbiological Success at EOT	Participant counts of clinical cure (no s/s of Candida) and microbiological success (eradication [f/u culture negative] or presumed eradication [f/u culture not available and a clinical response of cure]).	Day 14 up to Day 56
Secondary	Response Based on Clinical Cure and Microbiological Success at 2-Week Follow-Up Visit	Participant counts of clinical cure (no s/s of Candida) and microbiological success (eradication [f/u culture negative] or presumed eradication [f/u culture not available and a clinical response of cure]).	2 weeks post treatment
Secondary	Response Based on Clinical Cure and Microbiological Success at 6-Week Follow-Up Visit	Participant counts of clinical cure (no s/s of Candida) and microbiological success (eradication [f/u culture negative] or presumed eradication [f/u culture not available and a clinical response of cure]).	6 weeks post treatment
Secondary	Clinical Response at Day 10	Participant counts of clinical response categorized as success, failure, or indeterminate. Success: no s/s of Candida (cure) or significant but incomplete resolution of s/s of Candida; no additional systemic or oral antifungal treatment required (improvement). Failure: worsening of s/s of the Candida infection. Indeterminate: evaluation could not be made due to withdrawal from study prior to assessment of cure or failure. Participants who received fewer than 3 doses of study medication were assigned a clinical efficacy response of indeterminate.	Day 10
Secondary	Number of Participants With Recurrence	Participant counts of microbiologic response of recurrence defined as any baseline Candida sp isolated following eradication, or culture data were not available for participants with a clinical response of failure after a previous response of success. Clinical failure defined as =3 doses study medication and no significant improvement of s/s or death due to Candida. Clinical success is resolution of s/s and no additional antifungal treatment needed.	2 and 6 weeks post treatment
Secondary	Number of Participants With New Infections	Participant counts of microbiologic response of new infection defined as clinical failure with emergence of new Candida sp not identified at baseline at the original site of infection or at a distant site of infection. Clinical failure defined as =3 doses study medication and no significant improvement of s/s or death due to Candida.	2 and 6 weeks post treatment
Secondary	Time to First Negative Blood Culture for Candida Species	A participant had a negative blood culture, if having determined the day of the first negative blood culture, the subsequent blood culture was also negative, or if positive, the interval between the cultures was at least 2 days. For participants whose blood culture went from positive to negative, the time to negative blood culture defined as: date of first negative blood culture minus first treatment date plus 1.	Baseline up to Day 56
Secondary	Time to Death	Time to death defined as: date of death minus first treatment date plus 1.	Day 1 up to Day 98
Secondary	All-Cause Mortality	All-cause mortality during study therapy and at follow-up visits reported as unique deaths at EOIVT, end of oral treatment (EOT-oral), 2 Week Follow-Up and 6 Week Follow-Up	Baseline up to 6 weeks post treatment

External Links

•   To obtain contact information for a study center near you, click here.